CN107771071A - 用于向皮肤提供有益效果的多层局部施用的制品 - Google Patents
用于向皮肤提供有益效果的多层局部施用的制品 Download PDFInfo
- Publication number
- CN107771071A CN107771071A CN201680036309.3A CN201680036309A CN107771071A CN 107771071 A CN107771071 A CN 107771071A CN 201680036309 A CN201680036309 A CN 201680036309A CN 107771071 A CN107771071 A CN 107771071A
- Authority
- CN
- China
- Prior art keywords
- skin
- product
- product according
- top layer
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 43
- 230000003796 beauty Effects 0.000 claims abstract description 7
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- 210000003298 dental enamel Anatomy 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 abstract description 85
- 239000012790 adhesive layer Substances 0.000 abstract description 35
- 239000000047 product Substances 0.000 description 180
- 210000003491 skin Anatomy 0.000 description 153
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 239000000463 material Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- -1 galactolipin Chemical compound 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000019593 adhesiveness Nutrition 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000005452 bending Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 150000003851 azoles Chemical class 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000004492 retinoid derivatives Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 240000007817 Olea europaea Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 244000294611 Punica granatum Species 0.000 description 3
- 235000014360 Punica granatum Nutrition 0.000 description 3
- 235000010841 Silybum marianum Nutrition 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229940060037 fluorine Drugs 0.000 description 3
- 150000002314 glycerols Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001648859 Lilium candidum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027146 Melanoderma Diseases 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 235000002725 Olea europaea Nutrition 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000320380 Silybum Species 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000004178 amaranth Substances 0.000 description 2
- 235000012735 amaranth Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229950006229 chloroprednisone Drugs 0.000 description 2
- NPSLCOWKFFNQKK-ZPSUVKRCSA-N chloroprednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](Cl)C2=C1 NPSLCOWKFFNQKK-ZPSUVKRCSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 229960003238 fluprednidene Drugs 0.000 description 2
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013569 fruit product Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960004719 nandrolone Drugs 0.000 description 2
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- UBYZGUWQNIEQMH-SBBOJQDXSA-M potassium;(2s,3s,4s,5r)-2,3,4,5,6-pentahydroxy-6-oxohexanoate Chemical compound [K+].OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UBYZGUWQNIEQMH-SBBOJQDXSA-M 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 1
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 1
- WMSLPDVKMJABST-UHFFFAOYSA-N 4-iodobut-2-ynoic acid Chemical class OC(=O)C#CCI WMSLPDVKMJABST-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000303769 Amaranthus cruentus Species 0.000 description 1
- 235000015363 Amaranthus cruentus Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 229920001685 Amylomaize Polymers 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 244000157790 Buglossoides arvense Species 0.000 description 1
- 235000004256 Buglossoides arvense Nutrition 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 240000006122 Chenopodium album Species 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- ADFOLUXMYYCTRR-ZIAGYGMSSA-N Dihydroguaiaretic acid Natural products C1=C(O)C(OC)=CC(C[C@@H](C)[C@H](C)CC=2C=C(OC)C(O)=CC=2)=C1 ADFOLUXMYYCTRR-ZIAGYGMSSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 240000005074 Hymenocallis caribaea Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- 244000188472 Ilex paraguariensis Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 244000143590 Salvia chinensis Species 0.000 description 1
- 235000007154 Salvia chinensis Nutrition 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- LPNITZFOZWXKMB-UHFFFAOYSA-N acetic acid;molecular chlorine Chemical compound ClCl.CC(O)=O LPNITZFOZWXKMB-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- NWCHELUCVWSRRS-UHFFFAOYSA-N atrolactic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-UHFFFAOYSA-N 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RRTCFFFUTAGOSG-UHFFFAOYSA-N benzene;phenol Chemical compound C1=CC=CC=C1.OC1=CC=CC=C1 RRTCFFFUTAGOSG-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000019503 curry powder Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229950009888 dichlorisone Drugs 0.000 description 1
- YNNURTVKPVJVEI-GSLJADNHSA-N dichlorisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2Cl YNNURTVKPVJVEI-GSLJADNHSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960001440 fluclorolone Drugs 0.000 description 1
- VTWKPILBIUBMDS-OTJLYDAYSA-N fluclorolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(Cl)[C@@H](Cl)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 VTWKPILBIUBMDS-OTJLYDAYSA-N 0.000 description 1
- NJNWEGFJCGYWQT-VSXGLTOVSA-N fluclorolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1Cl NJNWEGFJCGYWQT-VSXGLTOVSA-N 0.000 description 1
- 229940094766 flucloronide Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960003590 fluperolone Drugs 0.000 description 1
- HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- FWFVLWGEFDIZMJ-FOMYWIRZSA-N hydrocortamate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CN(CC)CC)(O)[C@@]1(C)C[C@@H]2O FWFVLWGEFDIZMJ-FOMYWIRZSA-N 0.000 description 1
- 229950000208 hydrocortamate Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- ADFOLUXMYYCTRR-OKILXGFUSA-N meso-dihydroguaiaretic acid Chemical compound C1=C(O)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C(OC)C(O)=CC=2)=C1 ADFOLUXMYYCTRR-OKILXGFUSA-N 0.000 description 1
- XFEICBDAXKWVBZ-KGLIPLIRSA-N meso-dihydroguaiaretic acid Natural products COc1ccc(C[C@@H](C)[C@@H](C)Cc2ccc(O)c(OC)c2)cc1O XFEICBDAXKWVBZ-KGLIPLIRSA-N 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229940096421 milk thistle extract Drugs 0.000 description 1
- 235000020727 milk thistle extract Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VDGLSFJDSWHJFI-UHFFFAOYSA-N propan-2-one propan-2-yl propanoate Chemical compound CC(=O)C.C(C)(C)OC(CC)=O VDGLSFJDSWHJFI-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000037339 smooth wrinkles Effects 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019587 texture Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/0233—Distinct layers, e.g. core/shell sticks
- A61K8/0237—Striped compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8129—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8176—Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本文提供了一种适于在将制品局部施用到皮肤上时向皮肤提供美容和/或治疗有益效果的制品,该制品包括第一顶层和第二底部皮肤接触层,该第一顶层具有从皮肤面向外的顶表面和面朝皮肤的与顶表面相对的第二底表面,该第二底部皮肤接触层包括面向并且粘附到第一顶层的底表面的第一表面和用于当将制品施用到皮肤上时与皮肤接触并且将制品粘附到皮肤上的第二面向外的表面,其中底部皮肤接触层包含美容和/或治疗有益剂,第一顶层和第二底层中的每个包含水溶性成膜剂,并且制品在将水施用到所述皮肤上时能够从皮肤上容易地移除。
Description
技术领域
本发明涉及施用到消费者的皮肤上的施用部位上的自粘合多层制品,该制品向施用部位提供美容和/或治疗有益效果并且能够用水容易地移除。
背景技术
多种个人或消费者保健成分或组合物可施用到皮肤上以影响皮肤的健康或状况或外观或任何其它方面。它们经常以皮肤护理制剂的形式施用到皮肤上。皮肤护理制剂包括乳液(含水霜膏和洗剂)、糊剂和胶胨、无水霜膏和洗剂、膏剂、水/醇溶液或凝胶、喷剂、浆料以及粘剂。这些制剂在留在皮肤上一段时间以允许其中的多种成分、组合物或活性物质扩散到皮肤中。这些制剂的问题是,它们难以长时间段诸如一整天或过夜留在皮肤上。如果施用的部位与其它表面或制品诸如衣服接触,或在过夜使用期间与被褥(诸如被单或枕头)接触,则制剂可擦掉并且沾污与其接触的表面或制品。此外,洗剂、霜膏或膏剂经常是发粘的粘稠材料,该发粘的粘稠材料留下暴露在使用者的皮肤上时可拾取粉尘或污物或其它碎屑,导致使用者的不良的美观效果以及潜在的不适。最终,必须从皮肤上移除此类制剂,并且移除经常可需要不止简单地以普通的方式洗脸,并且可需要不止简单地使用水,诸如清洁剂和/或其它组合物、毛巾、面巾纸、棉球等。
皮肤护理产品可结合贴片递送。例如,局部成分或组合物可溶解在将贴片保持到治疗部位的粘合剂中,并且随时间推移可递送到治疗部位。此类贴片通常由非织造布、网片等一般不可溶解的材料形成。因此,将局部成分或组合物施用到使用者的皮肤上的这些形式的问题是,在治疗时间结束时片材或贴片的移除。具体地,使用者必须经常将贴片从皮肤上强力撕下以破坏贴片对皮肤的粘结。此撕裂经常导致使用者的不适并且甚至导致疼痛。疼痛可归因于敏感或脆弱的皮肤,其中粘着贴片的任何牵拉可引起皮肤损伤。而且,在具有显著量的毛发的皮肤部分中,强力移除粘附的局部贴片还可导致不期望的毛发的移除,从而还导致使用者的疼痛。
在专利文献中可广泛地得到作为必须从使用者的皮肤上剥离掉的贴片的上述缺点的解决方案的可溶解膜配方。典型的配方或专利描述了包含作为机械支撑(成膜剂)的一种或多种聚合物和允许可溶解膜在将干燥的膜施用到潮湿皮肤上时或在将干燥的膜连同适当的溶剂一起施用到皮肤上时具有粘合性的一种或多种粘合剂或发粘物质的基本上干燥的膜。
用于递送活性剂的单层快速溶解膜是已知的。膜包括成膜粘结剂、快速溶解聚合物材料和包含在膜层内的活性剂。在储存期间和施用之前,膜是非发粘的,并且因此在放置在皮肤或粘膜上时将不粘着到皮肤或黏膜上。
概括地说,皮肤是复杂的,并且向皮肤提供有益效果包括皮肤的治疗、包括单独或结合贴片使用粘稠制剂来将活性物质或其它局部成分或组合物递送到皮肤在效力或美学或使用者的舒适度上具有局限性。仍然需要局部施用的制品和/或递送系统,该局部施用的制品和/或递送系统易于使用(包括易于施用),可长期留在使用者上,并且一旦完成递送或在期望时还能够容易地移除。
发明内容
根据本发明,提供了适于在将制品局部施用到皮肤上时向皮肤提供美容和/或治疗有益效果的制品。制品包括第一顶层,该第一顶层具有从皮肤面向外的顶表面和面朝皮肤的与顶表面相对的第二底表面。制品还包括第二底部皮肤接触层,该第二底部皮肤接触层包括面向并粘附到第一顶层的底表面的第一表面和用于在将制品施用到皮肤上时使制品与皮肤接触并将制品粘附到皮肤上的第二面向外的表面。底部皮肤接触层包含至少一种有益剂,该至少一种有益剂选自由以下项组成的组:美容剂和治疗剂。第一顶层和第二底层中的每个包含水溶性成膜剂,并且该制品在将水施用到皮肤上时能够从皮肤上容易地移除。通过本发明的以下详细说明,所附权利要求书中阐述的发明范围,本发明的这些以及其它特征和优点将显而易见。
附图说明
结合附图将更好地理解详细说明,其中类似附图标记表示类似的构件,如下:
图1为本发明的制品的平面图;并且
图2为沿线2-2的图1的制品的剖视图。
图3为实施例16的结果的图形表示。
具体实施方式
图1和图2示出了本发明的制品100。在图1和2示出的实施方案中,制品100具有底部皮肤接触层120和顶层130,该顶层130具有从皮肤面向外的顶表面132和面朝皮肤的底表面134。皮肤接触层120具有在施用到使用者的皮肤上时粘附到其上的第一皮肤接触表面122。皮肤接触层120具有固定地附接到顶层130的底表面134的与第一皮肤接触表面122相对的第二表面124。
如上所示并且如本文下面另外所述,本发明的局部施用的制品优选地易于施用、佩戴舒适并且在将水施用到其上时能够容易地移除(即可崩解和/或可溶解)。应当理解,在本文提及“局部”应被理解为包括皮肤、黏膜和可施用本发明的制品的其它施用部位。
根据本发明更具体的方面,顶层的面向外的顶表面(即,背向制品所粘附到的消费者的皮肤的表面)不是发粘的,使得局部施用的制品在施用部位处保持在适当位置,不粘着到另一制品上,并且不从紧密围绕区域收集粉尘、污物或其它碎屑。优选地,局部施用的制品的底层对皮肤是自粘合的,即,粘附到皮肤上或至少容易地粘附到皮肤上,其中制品已经提供了标称水合程度。
以舒适、易于施用到施用部位上、如果需要的话保持在适当位置达延长的时间段(例如,至少半小时,或至少一小时,或至少约六(6)至八(8)小时,或至少约十二(12)小时,或约二十四(24)小时)的形式提供了图1和图2示出的局部施用的制品100。局部施用的制品在将水施用到其上时能够容易地移除。就能够容易地移除而言,其意指制品可在将水施用到制品上时溶解或崩解,使得其可从皮肤上移除而无需洗擦等。制品100优选地为相对柔性的局部施用的皮肤护理制品、贴片、贴花等(为了方便起见,而非旨在限制,下文中称为“制品”)。
如下面另外详细所述,本发明的制品优选地为相对薄的和柔性的,使得制品由于柔性和适形性两者以及薄而优选地容易地适形于使用者的皮肤并且佩戴舒适。旨在用于长期佩戴的本发明的制品还优选地形成为美学上高雅的,实际上不会剥落、起皱、破裂,或出现油腻或发粘,或以其它方式令人不愉快或不雅观的。制品优选地形成为具有足够的刚度和完整性以在皮肤上时能够经受正常的使用。例如,本发明的制品优选地形成为具有足够的强度以在暴露于皮肤可经历的正常的外力(例如,衣服、枕头等的摩擦)时在皮肤上保持完好。
优选地,本发明的制品相对易于施用到期望的施用部位。如果需要的话,则本发明的制品可形成以具有结构完整性。如本文所用,结构完整性应被理解为制品在独立于基底操作时并且优选地在施用到施用部位时,保持基本上整体式的形式或结构并且抵抗撕裂或破碎的物理能力。例如,本发明的制品可足够坚固以允许为了与任何支撑基底分离的期望目而进行处理,即优选地制品是自支撑的。如果使用支撑基底,则制品或制品优选地可从基底移除以独立于基底使用。
应当理解,如下面另外详细讨论的,本发明的制品的结构完整性优选地还有助于制品在操作和使用期间保持完好并且适形于施用制品的施用部位的轮廓的能力。例如,期望制品具有足够的结构完整性,使得制品在从基底上移除、操作、佩戴或以其它方式使用时不易撕裂。应当理解,选择有助于产品实现柔韧地、有胶粘力地且连续地覆盖在施用部位诸如皮肤上的能力的一种或多种成膜剂,是实现本发明的制品的期望的结构完整性的一种方式。除此之外或另选地,选择用于产生或促进塑性和柔性并且降低脆性的一种或多种增塑剂,是实现本发明的制品的期望的结构完整性的另一种方式。
本发明的制品的结构完整性通常可与制品的拉伸强度和厚度相关。与本发明有关的是,结构完整性通常随着厚度和屈服强度的增加而增加。然而,如下面另外详细讨论的,此类特性必须与它们对佩戴制品是否舒适的影响相平衡。拉伸强度有助于根据本发明的原理形成的制品的用于此类目的(诸如处理制品和/或将制品从基底上移除)的结构完整性。拉伸强度尤其影响制品在处理和/或从基底移除时能否抵抗破碎。例如,本发明的制品优选地具有约1,500psi至约5,000psi的弹性模量。在一个实施方案中已发现约2,500psi的弹性模量提供在使用期间舒适的期望硬度。具有3/4英寸(1.905cm)宽度和0.1mm厚度的典型样品具有约2lbf(磅力)的破裂强度,但应当理解,破裂强度的可用范围为约0.5lbf至约5lbf。制品的厚度也影响结构完整性。例如,本发明的制品的厚度可在约0.05mm至约2mm之间,并且优选地在约0.05mm至0.3mm之间。如下面另外详细讨论的,已发现大约0.1mm的厚度提供了用于处理、施用和最后移除制品的期望机械特性,使得制品在整个此类使用中以及在佩戴在给定的施用部位上时保持其结构完整性。
根据本发明的一个方面,本发明的制品是自粘合的,即它在与皮肤接触时粘附到使用者的皮肤上,而优选地无需另外的步骤,诸如添加另一种组合物诸如水。独特的粘合特性可由至少一种水溶性碳水化合物诸如糖类(单糖或二糖或低聚糖或多糖或它们的混合物)赋予。糖类具有Cx(H2O)y的化学式,其中结构式为H(CHOH)nC=O(CHOH)mH。示例包括衍生自不同植物源的淀粉、高直链淀粉(amylase)和高支链淀粉品种。如本文所用,术语“淀粉”还包括衍生自淀粉的水溶性成膜聚合物材料,该水溶性成膜聚合物材料包括淀粉衍生物诸如淀粉水解产物、改性淀粉、改性淀粉衍生物和麦芽糖糊精。优选水溶性碳水化合物低聚物。合适的水溶性碳水化合物低聚物包括木糖、核糖、葡萄糖、甘露糖、半乳糖、果糖、右旋糖、聚右旋糖、蔗糖、麦芽糖、玉米糖浆固体、帕拉金糖、山梨醇、木糖醇、甘露糖醇、麦芽糖醇、乳糖醇、黄原胶、麦芽糖糊精、半乳糖甘露聚糖、黄蓍胶、甘露醇、乳糖醇、低聚糖和水解胶体以及它们的混合物,诸如玉米糖浆、蜂蜜、高果糖玉米糖浆等。
在本发明的其中制品由含有葡萄糖的水溶性碳水化合物及其聚合物的混合物的玉米糖浆形成的实施方案中,膜的粘合特性一般依赖于其中含有水溶性碳水化合物的物质的含水量。在此类实施方案中,制品具有优选地在约6重量%至约15重量%的范围内的含水量,以提供足够的粘附性。低于此类范围通常不提供足够的粘附性,并且高于此类范围通常导致膜失去过多结构。
水溶性碳水化合物的优点是它们通过分子间键合和氢键合两种相互作用原位保留水分或水。令人惊奇地,适当量的水的存在,例如约6重量%至15重量%,为制品提供足以粘着到施用部位上而不会脱落的粘附性。水溶性碳水化合物还赋予柔软的柔韧质地,以允许制品适形任何表面轮廓或形状,同时保持适当的粘附性。
在一个实施方案中,可使用多糖。合适的多糖为非甜的胶状可溶类型的多糖,诸如天然树胶,例如阿拉伯胶、淀粉衍生物、糊精化和水解淀粉等。合适的多糖为水分散性改性的淀粉。
在一个实施方案中,水溶性生物粘合聚合物可用于增强皮肤粘合特性。可用于本发明的示例包括但不限于纤维素及其衍生物、聚乙烯吡咯烷酮、水溶性纤维素、聚乙烯醇、乙烯马来酸酐共聚物、甲基乙烯基醚马来酸酐共聚物、丙烯酸共聚物、甲基丙烯酸和甲基丙烯酸酯的阴离子聚合物、具有二甲基氨基乙基铵官能团的阳离子聚合物、聚环氧乙烷,水溶性聚酰胺或聚酯、聚乙二醇、水溶性丙烯酸聚合物、水溶性聚酯、羟烷基淀粉、酪蛋白、明胶、溶解蛋白、聚丙烯酰胺、聚胺类、聚季铵盐矿、苯乙烯马来酸酐树脂、聚乙烯胺类。水溶性碳水化合物可与膜中的水溶性或亲水性聚合物形成氢键合或共价键合。
根据本发明的一个方面,如本文上面讨论的,本发明的制品的粘合质量优选地能够将制品固定到使用者的皮肤上达延长的时间段,而不会刺激皮肤。优选地,只要合理和/或如所指示使制品处于在此类部位处的适当位置,制品就能够粘附到施用部位上。因此,由于使用者或佩戴者通常将希望在制品将自行从施用部位自然脱落之前移除制品,所以粘附时间的时间上限不重要。通常,将本发明的制品粘附到给定施用部位上的时间量由施用区域可经受不暴露于水的时间量决定。例如,应当理解,一些手术部位未暴露于水达延长的时间段,诸如几天。如果需要的话,只要部位未暴露于水,用于施用到此类部位的制品应相应地能够粘附到此类部位上。正如可理解的,与黏膜组织相比,优选地选择将粘合剂用于施用到通常认为非潮湿的皮肤表面上。应当理解,就能够粘附到使用者的皮肤上而言,如果对于具体施用来说此类特性是不期望或不必要的,则制品简单地能够粘附,而不需要必须粘附。
如上所述,由于本发明的制品优选地形成为保持粘附到施用部位上达延长的时间段,因此顶层的面向外的顶表面优选地具有期望的特性和特征以有利于制品的此类预期用途。例如,由于粘合制品或表面被设计为粘附到施用部位上,因此如果制品被设计为粘附到施用部位上达延长的时间段,则粘合的面向外的表面可在制品的使用期间不经意或无意地粘附到另一个表面或物体上。此类不经意或无意的事件可导致制品松脱,或更糟糕地从施用部位(部分或甚至完全)解脱。此外,应当理解,粘合材料通常吸引粉尘或污物或其它碎屑,佩戴者可将很可能认为这不雅观和不期望的。因此,优选的是本发明的制品的顶层的面向外的顶表面不是粘合的。因此,保持粘附到施用部位上达延长的时间段的本发明的制品优选地具有顶层的被覆盖或以其它方式致使非粘合的面向外的顶表面。
在一个实施方案中,在本发明制品的粘合皮肤接触层的面向外的表面之上设置有第三非粘合剥离层。应当理解,如果非粘合剥离层与粘合皮肤接触层(下文中,为了简单起见,简称为“皮肤接触层”)在将制品施用到皮肤上之前分离,则此类分离将很可能影响性能(例如,制品的外观、触觉特性(制品将是粘着的)以及半吸留性能(诸如下面讨论的))。因此,此类非粘合的面向外的剥离层优选地形成为保持与粘合皮肤接触层联接,直到当制品便于施用到皮肤上时为止。非粘合的面向外的剥离层可由在与其接触时不粘附到其它物体上的材料构成。优选地,面向外的层的粘合不随含水量改变或在暴露于不同的环境条件时不会改变。
如果面向外的层与某物摩擦或被某物摩擦或以其它方式与另一个表面或制品接触或被另一个表面或制品接触,则制品不应粘附到此类表面或制品上。如上所述,同样,面向外的剥离层应与粘合皮肤接触层充分地联接,如果面向外的剥离层与某物摩擦或被某物摩擦或以其它方式与另一个表面或制品接触或被另一个表面或制品接触,则面向外的剥离层不会与粘合皮肤接触层脱离。
制品可为有色调的或着色的以匹配使用者的肤色,使得其在佩戴时是美学上令人愉悦的、或至少不是不美观或不雅观的。该制品可形成为透光的以原位离散。可选择另外的特性,以致使本发明的制品在原位时视觉上离散,使得如果在白天佩戴制品,则尽可能地最小化其显著性。例如,制品越薄,通常越不易看见制品。此外或另选地,颜色、质地(例如,粗糙的、光滑的、平滑的或以其它方式具有纹理的诸如基本上匹配施用制品的皮肤的肌理使得制品相对于具有其天然瑕疵的皮肤并非明显平滑的“橘皮”表面)、光泽(有光泽的或阴暗的,取决于使用部位)等可根据需要进行修改,以有利于制品与施用部位的调和。由于本发明的制品可被配置成佩戴达延长的时间段(例如,超过一小时,诸如以上所述,和/或甚至过夜),因此制品优选地被形成或配置成当佩戴时是舒适的。在实现期望的舒适性和舒适度中可(单独地或以任何组合的方式)考虑多种因素,该因素包括但不限于触觉特性、材料厚度(不仅影响耐久性,还影响施用部位上的重量)以及硬度。可有助于舒适性的触觉特性包括用于将制品粘附到选择的施用部位上的粘合剂的平滑度和/或粘着性等。可有助于舒适性的另外的触觉特性包括膜的柔软度、平滑度和质地,诸如通过弹性模量和摩擦系数所确定的这些(而不仅仅是此类特性的美学方面)。
厚度影响多种另外的因素,该因素包括硬度-较硬的制品通常比较不硬的制品更不舒适。材料特性(材料的组成的函数,与形式无关)以及结构特性(制品的形式)可影响根据本发明的原理形成的制品在由使用者穿戴时可实现的舒适度。应当理解,根据本发明的原理形成的制品的所有期望的特性必须是平衡的,其中一些特性是互补的,而其它特性具有相反的量纲。关于舒适性,应当理解,有助于舒适性的特性必须与有助于结构完整性的特性相平衡。至少有三个影响“舒适性”的结构特性:柔性(关于单一弯曲方向;一般认为柔性是厚度和弯曲模量的组合),拉伸性(在单轴向上;一般认为拉伸性是厚度和弹性模量的组合)以及适形性(一般认为是关于复杂表面的在多个方向上的柔性和物理形状的组合)。舒适性可通过最小化厚度和弹性模量两者来实现。应当理解,柔性和拉伸性两者皆为材料的弹性模量的函数。更具体地,柔性一般由材料的厚度以及弯曲模量来决定。拉伸性是厚度和弹性模量的函数。当材料较厚时,硬度(该特性与舒适性相关)增加,并且柔性和拉伸性降低,一般对舒适性产生不利影响。弹性模量一般影响材料的橡胶化或脆性程度,并且由于其确定材料的柔性而与舒适性相关联。增加材料的弯曲模量或弹性模量分别使得材料的柔性或拉伸性更差。具体地,更高的弯曲模量或弹性模量导致更硬的材料,因此材料柔性更差并且可拉伸性更差。给定恒定的弯曲模量或弹性模量,更高的材料厚度将使材料的柔性或可拉伸性更差。正如可理解的,舒适性可通过将给定薄膜的厚度最小化到最低的实际限度来实现。下限通过提供足以处理和操作制品并足以有利于制品的施用和移除的结构来确定。从材料的角度来看,弹性模量与舒适性最密切联系。弹性模量越低,制品通常越舒适。约500PSI至约10,000PSI的弹性模量为使用者提供可接受的舒适度,其中更优选的弹性模量范围为约1000PSI至约5000PSI,其中优选的弹性模量为约2500PSI。适形性诸如适形于给定部位(通常为具有复杂曲率的表面)的能力,一般来讲不仅涉及柔性,还涉及多方向的柔性和拉伸性(例如,如果制品放置在关节上,则制品可拉伸)。适形性一般必须根据施用部位的物理形状或轮廓来定义,并且相对于表面连同柔性一起来确定。制品可需要具有特定的平面形状以能够适形于复杂表面。优选地,根据本发明的原理形成的制品在所有方向上具有基本上相同的特性。
如果将根据本发明的原理形成的制品保持在施用部位上达延长的时间段,则此类制品优选地具有期望的透气程度。对于制品在提供此类有益效果方面的功能性,透气性对于获得期望的皮肤保湿性或适当的皮肤含水量平衡也是重要的。透气性涉及氧交换并且是氧交换的函数,其影响皮肤屏障以及消费者看法。透气性还是水传输的函数。根据本发明的原理形成的制品优选地是足够透气的,使得皮肤水分含量保持平衡。当然,如下面另外详细讨论的,如果使用本发明的期望结果中的一个是改善或增加皮肤含水量,则优选地可选择制品的透气性以有利于此类保湿性。半吸留膜将至少部分地抑制水流失并且因此将水分保持在皮肤内。根据本发明的原理形成的制品优选地提供对水分传输的抵抗,并且可具有每小时每平方米大约50克至150克水的水分传输速率。已发现此类制品阻挡或阻塞在没有膜屏障的情况下将发生的蒸发的大约87%。
如下面另外所述,根据本发明的原理形成的制品可为半吸留的(优选地大约85%的吸留),不仅保持透气性,而且提供发现的由用半吸留制品覆盖施用部位产生的其它有益效果。如果制品形成具为有面向外的剥离层,则此类剥离层还可有助于制品的总体半吸留性质。具体地,面向外的层可连同吸湿性皮肤接触层一起起作用。一旦此类皮肤接触层另外水合,它就可另外失去结构完整性,并且独立于面向外的层从膜型物质转化成不具有结构完整性的凝胶相。因此,面向外的层实质上封盖并包含施用部位处的皮肤接触表面,使得皮肤接触表面可使施用部位水合。
本发明的制品仅通过添加水来溶解或崩解。优选地,不需要机械搅拌以有利于制品的移除。优选地,在不存在制品的条件下用于施用部位的典型消费者洗涤方案的参数内,本发明的制品优选地完全溶解,因此消费者不需要另外的洗涤时间。优选地,本发明的制品是快速溶解的以便于从使用者的施用部位移除(当洗脸时,优选地在将水添加到制品后少于约5分钟,并且甚至少于约1分钟,并且甚至约30秒。应当理解,对于通常洗涤超过5分钟的其它身体部分上的部位,更长的溶解速率是可接受的,但是优选地不需要洗擦如此长的溶解时间以实现移除)。在约4ft/s的模拟的清洗水流速(平行流动到膜表面)的情况下,经测量在约67秒内完全溶解,其中外面的膜表面在约30秒时发生初始破坏。在另一个实施方案中,可用由织造或非织造材料制成的湿布、片材或垫来移除膜。
如本文说明书和权利要求书所用,术语“水能够移除的”及其变型意指在室温(21℃)下,以4英尺/秒的水流量(平行于制品的顶表面)在少于90秒内将制品从其所粘附到的表面移除。
膜的主要机械强度由成膜剂(在面向外的层中优选聚乙烯醇(PVA))产生,该成膜剂通常也根据需要基于其允许制品便于分解的能力来进行选择。应当理解,在一个实施方案中,优选地选择成膜剂以实现期望的使制品溶解或崩解的能力,以便在将水施用到制品上时将其移除,并且成膜剂可为所选择的制品组合物的第一组分,选择其它组分以根据需要与已经选择的成膜剂相互作用。柔性通过将增塑剂诸如甘油添加到成膜剂中来实现。成膜剂和/或增塑剂通常是结构完整性的主要贡献者,并且通常是用于形成具有如上所述的特性的面向外的顶层的组合物的组分。下面更详细地列出了示例性成膜剂和增塑剂。参见固体含量,按根据本发明原理形成的制品的干燥成分的重量计,PVA可为70%,其中甘油为20重量%。按制品的重量计,甘油可在低至10%至30%的范围内,按干燥成分的重量计,PVA可多达90%。
应当理解,选择皮肤接触层120和面向外的层130使得它们联接在一起以形成整体结构。优选地,皮肤接触层120和面向外的层130在制品100的操作期间不仅不彼此脱离,而且也不相对于彼此移位。例如,如果某物摩擦面向外的层130或面向外的层130摩擦某物,则面向外的层130应足够强地联接到皮肤接触层120,使得面向外的层130不与皮肤接触层120脱离。在一个实施方案中,选择制品100对施用部位的粘附强度,使其比皮肤接触层120和面向外的层130对彼此的粘附强度弱。两个层之间的粘结本质上产生不可分离的并且作为单个一体的整体式制品起作用的单个产品。
根据本发明的一个方面,皮肤接触层120和面向外的层130使用相同的溶剂形成,使得两层制品100无论是在形成皮肤接触层120和面向外的层130的组合物两者皆处于湿态时,还是在皮肤接触层120和面向外的层130的组合物中的一者处于湿态且皮肤接触层120和面向外的层130的组合物中的另一个处于干态时形成的,在层界面处的两种组分之间仍将有一定量的分子水平上的混合。因此,优选地选择皮肤接触层120和面向外的层130的原材料,使得它们相互混合至皮肤接触层120和面向外的层130在使用前或在使用期间保持联接在一起且不分离的程度。优选地,两个层皆为水溶性的,使得可发生一定水平的混合(优选地在分子水平上)以产生层之间的期望粘结。然而,应当理解,在分子水平上相互混合并非实现层之间的期望粘结所必需的。
根据本发明,多层局部皮肤制品包括皮肤接触层(底部)和与皮肤接触层相对并背向皮肤接触层的面向外的层(顶部)。皮肤接触层优选地包含亲水性成膜聚合物、使膜中的其它成分溶解的增溶剂、崩解促进剂、增稠剂/结构化剂/质地改性剂,保持皮肤水分的吸湿剂/润湿剂、驱使吸湿剂进入皮肤中的分配系数改性剂/吸收或渗透促进物质、用于柔性和柔软度的增塑剂/主要粘合剂、用于水胶体并且用于保持潜在水分并保有最终制品柔性的溶剂以及其它助剂或添加剂。皮肤接触层优选直接施用到皮肤表面上,并且具有适于用作制品的皮肤接触表面的特性。此类特性包括快速溶解、持久的粘附强度、半吸留性和柔性。皮肤接触层还可包含可通过皮肤接触层递送到皮肤的美容活性剂。
面向外的层具有适于用作用于多层局部皮肤制品的物理屏障的特性,当制品保持在施用部位上的适当位置时,允许其保持无粉尘和污物以及碎屑。此类特性包括快速溶解、半吸留性、柔性和非粘着性。面向外的层包含亲水性成膜聚合物、崩解促进剂、水包油乳化剂、限制水从皮肤接触层向局部层迁移的蜡、用于柔性和柔软度的增塑剂、主要的粘合剂、用于水胶体并且用于保持潜在水分并保有最终制品柔性的溶剂以及其它助剂或添加剂。
用于制备本发明的多层局部皮肤制品的亲水性成膜聚合物快速溶解于水中,并且形成容易地粘附到皮肤表面上的发粘的凝胶或粘着的凝胶。皮肤接触层的可溶解于水的亲水性成膜聚合物在与皮肤表面接触时,通过水合过程与皮肤表面水分中的水组分相互作用。水合力提供帮助皮肤接触层粘附到皮肤表面上的粘合相互作用。
适于生产多层局部皮肤制品的亲水性成膜聚合物可为合成的、半合成的或天然来源的。此类亲水性成膜聚合物包括但不限于纤维素醚、聚乙烯醇、聚乙酸乙烯酯、聚乙烯吡咯烷酮、多糖以及它们的衍生物、共聚物或聚合物。可将多层局部皮肤制品制成包括但不限于膜形式的广泛多种产品形式。
膜的粘附性通过成膜剂(诸如聚乙烯吡咯烷酮)、用于初始发粘或粘着性的增粘剂(诸如玉米糖浆)、使配方更有柔性并且有助于溶解性的增塑剂(诸如甘油)以及最终确保膜在更宽的含水量范围内基本上保持其物理特性的更疏水的成分的组合来实现。
在一个实施方案中,本发明制品的粘附性通过提供高果糖玉米糖浆作为制品的成分来实现。与干燥之后在膜中剩下的残余水分结合的玉米糖浆使得制品表现出期望的粘合特性并且赋予制品100粘合质量。
于2014年12月23日提交的题为“用于形成多层成型的膜产品的方法”(“PROCESSFOR FORMING A MULTILAYED SHAPED FILM PRODUCT”)的美国专利申请序列No.14/580,977和于2014年12月23日提交的题为“用于形成多层成型的膜产品的单程方法”(“SINGLE-PASSPROCESS FOR FORMING A MULTILAYERED SHAPED FILM PRODUCT”)的美国专利申请序列No.14/581,010中讨论了形成本发明的两层制品的示例性方法,这两个专利申请的全部内容均以引用方式并入本文。
根据本发明的一个实施方案,可通过浇注并干燥粘合层,并且然后将顶层浇注在底层的顶部上来形成制品。两个层通过已知的粘附方法(机械的、化学的、分散的、静电的、扩散的等)中的任一种彼此粘附。在一个实施方案中,两个层优选地都是水溶性的,使得非粘合的面向外的层中的水将稍微溶解已经干燥的粘合皮肤接触层,从而在两个层的界面处产生一定量的扩散粘附。在本发明的第二个实施方案中,湿碰湿地浇注两个层,并且在两个层之间的界面处发生材料的相互混合,从而通过扩散粘附产生粘结。优选地,材料具有共同的溶剂和/或彼此可混溶,使得它们相互混合并且粘结在一起。应当理解,粘合层和非粘合层(分别为皮肤接触层和面向外的层)的材料可具有除水之外的共同溶剂,诸如醇,使得材料彼此粘结。
可用于本发明的制品中的有益剂包括美容剂和治疗剂。如本文所用,有益剂意指提供有益效果例如在美容方面或在治疗方面改善、减轻、减少或治疗皮肤的症状或状况的成分或材料。此类物质可为包括而不限于以下多种组合物中的任一种:透明质酸;羟基酸(例如,羟基乙酸、乳酸、苹果酸、水杨酸、柠檬酸、酒石酸);抗痤疮剂(例如,水杨酸、视黄醇、类视色素或其它角质层分离剂以及过氧化苯甲酰或用于治疗痤疮的其它抗微生物剂);光泽控制剂(例如,稻米蛋白、棉粉、新康唑(二氯苯基-二氧戊环咪唑);类视色素或其衍生物,诸如维甲酸、异维甲酸、莫维胺、阿达帕林、他佐罗汀、壬二酸和视黄醇;氨基酸的5-α-还原酶抑制剂,例如甘氨酸衍生物;包括大豆蛋白和小麦蛋白等的水解植物蛋白;绿茶(camellia sinesis)提取物和肉桂树皮提取物);保湿剂;抗微生物剂(例如,阳离子抗微生物剂,诸如苯扎氯铵、苄索氯铵、三氯卡班、聚六亚甲基双胍、十六烷基氯化吡啶鎓、甲苄索氯铵;氯己定的盐,诸如碘代丙炔基氨基甲酸酯、双咪唑烷基脲、葡萄糖酸氯己定、乙酸氯己定、羟乙磺酸氯已定和盐酸氯已定;卤代酚类化合物,诸如2,4,4',-三氯-2-羟基二苯醚(三氯生(Triclosan));对氯间二甲苯酚(PCMX);短链醇诸如乙醇、丙醇等);抗生素或防腐剂(莫匹罗星、硫酸新霉素杆菌肽、多粘菌素B、1-氧氟沙星、四环素(盐酸金霉素、10-盐酸土霉素和盐酸四环素)、磷酸克林霉素、硫酸庆大霉素、甲硝唑、己基间苯二酚、甲苄索氯铵、苯酚、季铵化合物、茶树油以及它们药学上可接受的盐和前药)、抗炎剂(例如,合适的类固醇类抗炎剂,诸如皮质类固醇诸如氢化可的松、羟基去炎松α-甲基地塞米松、磷酸地塞米松、二丙酸倍氯米松、戊酸氯倍他索、地奈德、脱氧米松、乙酸去氧皮质酮、地塞米松、二氯松、二乙酸二氟拉松、戊酸二氟可龙、氟氢松、氟氯缩松缩丙酮化物、氟氢可的松、新戊酸氟美松、氟西诺龙缩丙酮化物、乙酸氟轻松、氟可丁酯、氟可龙、乙酸氟泼尼定(氟强的松(fluprednylidene))、氟氢缩松、哈西奈德、乙酸氢化可的松、丁酸氢化可的松、甲泼尼龙、曲安奈德、可的松、可托多松、氟塞耐德、氟氢可的松、二乙酸二氟松、氟氢松奈德、甲羟松、安西法尔、安西非特、倍他米松、氯泼尼松、乙酸氯泼尼松、氯可托龙、克西诺龙(clescinolone)、双氯松、二氟泼尼酯、氟二氯松、氟尼缩松、氟米龙、氟培龙、氟泼尼龙、戊酸氢化可的松、环戊基丙酸氢化可的松、氢可松氨酯、甲泼尼松、帕拉米松、泼尼松龙、泼尼松、二丙酸倍氯米松、二丙酸倍他米松、去炎松以及盐;非类固醇类抗炎剂,小白菊(解热菊(Tanacetum parthenium))、枸杞果(宁夏枸杞(Lycium barbarum))、水飞蓟提取物(水飞蓟(Silybum marianum))、苋菜油(繁穗苋(Amaranthus cruentus))、石榴(安石榴(Punicagranatum))、马黛茶(巴拉圭茶叶(Ilex paraguariensis Leaf)提取物)、白百合花卉提取物(白百合(Lilium Candidum))、橄榄叶提取物(油橄榄(Olea europaea))、根皮素(苹果提取物));抗霉菌/抗真菌剂(例如,咪康唑、益康唑、酮康唑、舍他康唑、伊曲康唑、氟康唑、伏立康唑、氯碘羟喹、比佛那唑(bifoconazole)、特康唑、布康唑、噻康唑、奥昔康唑、硫康唑、沙康唑、克霉唑、十一烯酸、卤普罗近、布替萘芬、托萘酯、制霉菌素、环吡酮胺、特比萘芬、阿莫罗芬、萘替芬、新康唑、灰黄霉素、以及它们的药学上可接受的盐和前药;唑、烯丙胺或它们的混合物);外用止痛药(例如,布洛芬或双氯芬酸;辣椒素、芬太尼及其盐诸如枸橼酸芬太尼;对乙酰氨基酚(如扑热息痛);非类固醇类抗炎药(NSAID)诸如水杨酸盐;阿片类药物诸如吗啡和羟考酮;含布洛芬或双氯芬酸的凝胶);抗氧化剂(例如,巯基化合物及其衍生物(例如,焦亚硫酸钠和N-乙酰半胱氨酸)、硫辛酸和二氢硫辛酸、白藜芦醇、乳铁蛋白;抗坏血酸、抗坏血酸酯和抗坏血酸衍生物(例如,抗坏血酸棕榈酸酯和抗坏血酸多肽);丁基羟基苯甲醚、丁基化羟基甲苯(丁基羟基甲苯(butylhydroxy toluene))、类视色素(例如,视黄醇和棕榈酸视黄酯)、生育酚(例如,生育酚乙酸酯)、生育三烯酚和泛醌;半胱氨酸、N-乙酰半胱氨酸、亚硫酸氢钠、焦亚硫酸钠、甲醛次硫酸氢钠、丙酮合亚硫酸氢钠、生育酚和去甲二氢愈创木酸;含类黄酮和异黄酮及其衍生物(例如,染料木黄酮和黄豆苷元)的提取物;含白藜芦醇等的提取物;葡萄、绿茶、松树皮和蜂胶;植物来源的多酚抗氧化剂诸如丁香、肉桂、牛至、姜黄、小茴香、欧芹、罗勒属植物、咖喱粉、芥菜籽、姜、辣椒、辣椒粉、红辣椒、大蒜、芫荽、洋葱和小豆蔻;典型的香草诸如鼠尾草、百里香、牛膝草、龙蒿、胡椒薄荷、牛至、香薄荷、罗勒属植物和莳萝叶));脱毛剂(例如,巯基乙醇酸钙或巯基醇酸钾);维生素(例如,维生素A、维生素B、维生素C、维生素E;或α-生育酚、β-生育酚、γ-生育酚或δ-生育酚、烟酸或烟酰胺)和维生素盐或衍生物诸如抗坏血酸二葡糖苷和维生素E乙酸酯或维生素E棕榈酸酯;防晒剂(例如,二氧化钛)和/或遮光剂(例如,无机遮光剂诸如二氧化钛和氧化锌;有机遮光剂诸如辛基-甲氧基肉桂酸酯、水杨酸辛酯、胡莫柳酯、阿伏苯宗);血管扩张剂(例如,烟酸):湿润剂(例如,甘油);抗衰老剂(例如,类视色素;二甲基氨乙醇(DMAE),含铜的肽);α-羟基酸或果酸及其前体诸如乙醇酸、柠檬酸、乳酸、苹果酸、扁桃酸、抗坏血酸、α-羟基丁酸、α-羟基异丁酸、α-羟基异己酸、阿卓乳酸、α-羟基异戊酸、丙酮酸乙酯、半乳糖醛酸、葡庚糖酸、葡萄七酮并1,4-内酯、葡糖酸、葡糖酸内酯、葡糖醛酸、葡糖醛酸内酯、丙酮酸异丙酯、丙酮酸甲酯、粘酸、丙酮酸、葡糖二酸、葡糖二酸1,4-内酯、酒石酸和丙醇二酸;β-羟基酸诸如β-羟基丁酸、β-苯基-乳酸和β-苯基丙酮酸;锌和含锌的化合物诸如氧化锌;植物提取物诸如绿茶、大豆、水飞蓟、藻类、芦荟、当归、苦橙、咖啡、黄连、西柚、茯苓(hoellen)、忍冬、薏苡、紫草、桑树、芍药、葛根、nice和红花以及它们的盐和前药);类胡萝卜素、神经酰胺、脂肪酸、酶、酶抑制剂、矿物质、类固醇、肽、氨基酸、植物提取物、着色剂等。物质可以多种方式中的任一种来影响皮肤,诸如通过保湿;增强肤色或着色(诸如用颜料);治疗或至少缓解各种皮肤状况(诸如干燥或严重干燥的皮肤、湿疹、牛皮癣、特应性皮炎、过敏性皮疹、痤疮、黑头、脓疱、粉刺、红斑痤疮、带状疱疹、皱纹、唇疱疹、疱疹、鸡眼、疣、晒斑、昆虫叮咬、毒葛等);施加机械力以平滑皱纹;或更一般地,治疗或缓解不希望的皮肤瑕疵症状或出现(诸如眼下黑眼圈、痤疮发红、细纹和皱纹、发炎后色素沉着过度(PIH)、发红、炎症、脂肪团、皱纹、老年斑、斑状色素沉着、黑斑、雀斑、眼下浮肿);移除不想要的面部或身体毛发;帮助创伤愈合;等。例如,可将洗剂、霜膏、油甚至面膜施用到皮肤上来治疗或以其它方式影响皮肤。此类个人或消费者保健物质一般遵循扩散原理吸收到皮肤中,在该扩散原理下,穿过皮肤的扩散或输送速率与皮肤两侧上的活性物质浓度差相关。
可通过使用一种或多种乳化剂诸如甘油衍生物来增强有益剂从制品向哺乳动物身体的转移,该甘油衍生物包括但不限于甘油酯诸如单甘油酯(例如,MYVEROL 18-99)和甘油脂肪酸酯诸如甘油油酸酯(MONOMULS 90-O 18,可购自BASF Corporation,FlorhamPark,New Jersey,USA)。据信,这些组分有助于将有益剂从皮肤接触层释放到皮肤中。使用者可将制品施用到哺乳动物身体上的施用部位(诸如人体皮肤或黏膜)上,并且如果需要的话允许制品保持在适当位置达延长的时间段(例如,至少半小时,或至少一小时,或至少约六(6)至八(8)小时,或至少约十二(12)小时,或约二十四(24)小时)。然后,局部施用的制品在将水施用到其上时能够容易地移除。就能够容易地移除而言,其意指制品可在将水施用到制品上时溶解或崩解,使得其可从皮肤上移除而无需洗擦等。令人惊奇地,如下面实施例所示,此长期佩戴可显著增强皮肤治疗的功效。
将通过参照以下具体的实施例另外理解本发明,该实施例是制备本发明的组成、形式和方法的例示性实施例。应当理解,制备本发明的组成、形式和方法的多种变型对本领域的技术人员来说将是显而易见的。除非另外指明,否则以下的实施例仅仅是例示性的,其中份数和百分数均以重量计。
实施例
表1:实施例中形成的膜的总结。
实施例1:保湿膜
表1a:用于顶层的配方。
表1b:用于底层的配方。
实施例2:抗衰老皮肤美白膜。
表2a:用于顶层的配方。
表2b:用于底层的配方。
实施例3:抗痤疮膜。
表3a:用于顶层的配方。
表3b:用于底层的配方。
实施例4:抗衰老皮肤美白膜。
表4a:用于顶层的配方。
表4b:用于底层的配方。
实施例5:抗皱纹抗衰老膜。
表5a:用于顶层的配方。
表5b:用于底层的配方。
实施例6:布洛芬递送膜。
表6a:用于顶层的配方。
表6b:用于底层的配方。
实施例7:氧化再生纤维素(ORC)止血膜。
表7a:用于顶层的配方。
表7b:用于底层的配方。
实施例8:皮肤护理基膜。
表8a:用于顶层的配方。
表8b:用于底层的配方。
实施例9:抗衰老皮肤美白膜。
表9a:用于顶层的配方。
表9b:用于底层的配方。
实施例10:抗微生物膜。
表10a:用于顶层的配方。
表10b:用于底层的配方。
实施例11:牛皮癣治疗膜。
表11a:用于顶层的配方。
表11b:用于底层的配方。
实施例12:湿疹治疗膜。
表12a:用于顶层的配方。
表12b:用于底层的配方。
实施例13:保湿膜。
表13a:用于顶层的配方。
表13b:用于底层的配方。
实施例14:抗衰老皮肤美白膜。
表14a:用于顶层的配方。
表14b:用于底层的配方。
实施例15
双单元临床研究(two-cell clinical study)经过八周的疗程比较了安慰剂制品和含己基间苯二酚的制品。每个单元有15个受试者,每隔一晚给予该受试者膜以放置在他们脸上的黑点上,并且在早上洗掉。使用MoistureMeterD XS5探针(Delfin Technologies,Kuopio,Finland)来评估膜的水分有益效果,并且通过单个受试者问卷测量感知的有益效果。
两个测试单元制品皆由两层形成,并且用于每个测试单元的顶层是相同的:
用于顶层的配方。
表15a:用于顶层的配方。
配方12924-120 | |
成分 | 式量% |
Selvol 805 | 27.20 |
聚山梨酸酯80 | 2.07 |
Dow Corning 2501美容蜡 | 0.95 |
凯斯特蜡K-24 | 0.95 |
甘油,99.7%,USP | 2.52 |
纯化水 | 66.31 |
100 |
用于安慰剂制品的底部配方
表15b:用于底层的配方。
用于本发明制品的底部配方
表15c:用于底层的配方。
使用8周后,相比于23.1%的使用安慰剂斑点治疗的受试者,81.3%的使用己基间苯二酚斑点治疗的受试者认为色度调整产品有助于明显减少他们的黑斑的出现。
8周后,100%的受试者证实他们的皮肤的含水量增加。
实施例16
在掺有甘油衍生物乳化剂的制品与没有此类乳化剂的制品之间进行比较,其中对照物为可商购得的己基间苯二酚产品( Triple Age Repair)。用于所有制品的顶层都与实施例15(配方1294-120,表15a)相同。
用于底层的配方如下:
实施例16A(己基间苯二酚/Myverol 18-99),配方12924-021
表16a:用于实施例16A的底层的配方(己基间苯二酚/Myverol
18-99)
实施例16B(己基间苯二酚/Monomuls 90-O18),配方12924-021
表16b:用于实施例16A的底层的配方(己基间苯二酚/Monomuls 90-O18)。
实施例16C(己基间苯二酚/无乳化剂),配方13237-097
表16c:用于实施例16A的底层的配方(己基间苯二酚/Monomuls 90-O18)。
通过以下方案测试这些产品:
·用70%的乙醇、水和受体溶液(1X PBS,磷酸盐缓冲盐水)洗涤Franz池。
·测量皮肤厚度和电阻
·将组织安装在Franz池上(n=4)。
·一旦平衡后,就通过用Kimwipes擦拭皮肤表面来确保组织表面(SC)上没有多余的水分。
·小心移除膜上的背衬,并且用轻微的压力(在皮肤表面上轻拍5次)将其放置在供体区域;粘合侧与皮肤接触。
·安装供体室并且使其过夜
·第二天早上(16h时间点后),取样(300uL)(0h),用新鲜的1X PBS替换。
·将100uL的1X PBS添加到供体室,静置30秒,使用塑料吸移管围绕供体的边缘移动来将其移除。重复此循环5次。储集这些1XPBS溶液并且通过HPLC进行分析
·移除供体室,其中组织仍安装在Franz池上。使用棉拭子去掉所有保持在皮肤上的液体。通过在2mL乙醇:水(50:50v/v)中以100rpm的速度振荡过夜来从该拭子中提取药物。
·将供体室放回。每隔2小时(2h、4h、6h)后,取样(300uL)并且用新鲜受体溶液替换。
·在22小时,移除供体室,从池中取出皮肤,将皮肤放在纸片上,并且用2个条带进行条带剥离以移除皮肤表面上的过量药物。将这两个条带放入6孔板的孔中以用于提取。
·使用镊子将表皮和真皮分离。通过剪刀将它们剪碎。将它们单独地储集到6孔板中。
·添加2ml乙醇:水(50:50v/v)以用于提取过夜,速度为100rpm。
·通过0.45um的过滤器过滤样品并且运行HPLC
膜提取研究
·将3个膜与背衬层分离(n=3)
·将它们单独地放置在6孔板中。
·与用于皮肤提取一样,添加2ml乙醇:水(50:50v/v)并且以100rpm的速度提取过夜。
·注入HPLC中并且分析结果。
注意:标准曲线和提取溶剂为乙醇:水(50:50v/v)
在6孔板上:
·2个条带
·表皮
·真皮
·棉拭子
Triple Age Repair(1%己基间苯二酚)用作局部对照物,并且以与测试膜制品类似的方式将其施用到测试组织上。
结果在图3中以图形示出。可见,与实施例16C相比,使用乳化剂(Myverol或Monumuls)极大地增强了己基间苯二酚的递送。此外,经由实施例16A和实施例16B的膜制品递送的己基间苯二酚类似于经由局部对照物递送的己基间苯二酚。
虽然前述说明书和附图表示本发明的示例性实施方案,但应当理解,在不脱离本发明的实质和范围的情况下,可对本发明做各种添加、修改和替换。因此,当前公开的实施方案在各方面被认为是例示性的而非限制性的,本发明的范围由所附权利要求书指出,且不受前述描述的限制。
Claims (12)
1.一种适于在将制品局部施用到皮肤上时向所述皮肤提供美容和/或治疗有益效果的制品,所述制品包括:
第一顶层,所述第一顶层具有从所述皮肤面向外的顶表面和面朝所述皮肤的与所述顶表面相对的第二底表面,
第二底层,所述第二底层包括面向并且粘附到所述第一顶层的所述底表面的第一表面和用于当将所述制品施用到所述皮肤上时与所述皮肤接触并且将所述制品粘附到所述皮肤上的第二面向外的表面,所述第二底层包含至少一种有益剂,所述至少一种有益剂选自由以下项组成的组:美容剂和治疗剂,
其中所述第一顶层和所述第二底层中的每个包含水溶性成膜剂,并且所述制品在将水施用到所述皮肤上时能够从所述皮肤上容易地移除。
2.根据权利要求1所述的制品,其中所述第二底层还包含有效量的乳化剂以增强所述有益剂从所述第二底层的输送。
3.根据权利要求2所述的制品,其中所述乳化剂为甘油衍生物。
4.根据权利要求3所述的制品,其中所述乳化剂为选自由甘油酯和甘油脂肪酸酯构成的组。
5.根据权利要求1所述的制品,其中所述至少一种有益剂包括己基间苯二酚。
6.根据权利要求1所述的制品,其中所述至少一种有益剂包括烟酰胺。
7.根据权利要求1所述的制品,其中所述至少一种有益剂包括水杨酸。
8.根据权利要求1所述的制品,其中所述至少一种有益剂包括止痛药。
9.根据权利要求8所述的制品,其中所述止痛药包括布洛芬。
10.根据权利要求1所述的制品,其中所述至少一种有益剂包括多个有益剂。
11.根据权利要求1所述的制品,其中所述顶层包含聚乙烯醇。
12.根据权利要求1所述的制品,其中所述底层包含聚乙烯吡咯烷酮。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562182888P | 2015-06-22 | 2015-06-22 | |
US62/182,888 | 2015-06-22 | ||
PCT/US2016/038642 WO2016209880A1 (en) | 2015-06-22 | 2016-06-22 | Multi-layer topically-applied article for providing a benefit to skin |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107771071A true CN107771071A (zh) | 2018-03-06 |
Family
ID=56369204
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680036309.3A Pending CN107771071A (zh) | 2015-06-22 | 2016-06-22 | 用于向皮肤提供有益效果的多层局部施用的制品 |
CN201680036271.XA Pending CN107771070A (zh) | 2015-06-22 | 2016-06-22 | 用于向皮肤提供有益效果的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680036271.XA Pending CN107771070A (zh) | 2015-06-22 | 2016-06-22 | 用于向皮肤提供有益效果的方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20160367490A1 (zh) |
EP (2) | EP3310327A2 (zh) |
JP (2) | JP2018519294A (zh) |
KR (2) | KR20180018793A (zh) |
CN (2) | CN107771071A (zh) |
AU (2) | AU2016284311B2 (zh) |
BR (2) | BR112017027750B8 (zh) |
CA (2) | CA2988152A1 (zh) |
HK (2) | HK1252628A1 (zh) |
MA (2) | MA45906A (zh) |
MX (2) | MX2017016787A (zh) |
RU (2) | RU2704809C2 (zh) |
WO (2) | WO2016209882A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112752571A (zh) * | 2018-07-03 | 2021-05-04 | 蓝莓疗法有限公司 | 组合物和治疗方法 |
CN114025851A (zh) * | 2019-07-03 | 2022-02-08 | 株式会社资生堂 | 保湿用膜化妆料 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596134B2 (en) | 2017-02-08 | 2020-03-24 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and polycarboxylic acids |
JP7253714B2 (ja) * | 2018-05-17 | 2023-04-07 | パナソニックIpマネジメント株式会社 | 生体貼付用膜及び生体貼付用膜を貼り付ける美容方法 |
US10813435B2 (en) | 2018-06-06 | 2020-10-27 | Janet Kranes | Device for tightening loose neck skin and method of using the same |
US11241374B2 (en) | 2018-06-28 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride |
CN109498834B (zh) * | 2018-12-14 | 2021-10-08 | 广州润虹医药科技股份有限公司 | 一种抑菌水胶体敷料及其制备方法 |
KR102245629B1 (ko) * | 2019-04-10 | 2021-04-30 | 주식회사 제네웰 | 히알루론산계 녹는 필름, 이의 제조방법 및 이에 사용되는 이형지 |
US10537534B1 (en) | 2019-06-25 | 2020-01-21 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using visible light and resorcinols |
US20200405603A1 (en) | 2019-06-25 | 2020-12-31 | Johnson & Johnson Consumer Inc. | Compositions and methods for treating skin conditions using infrared light and resorcinols |
KR102212787B1 (ko) * | 2020-10-15 | 2021-02-08 | (주)제이에이치사이언스 | 미백 기능의 필링제 조성물 |
CN113786512B (zh) * | 2021-09-24 | 2022-05-24 | 华南理工大学 | 一种低压式原位抑菌促修复电纺敷料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006009987A2 (en) * | 2004-06-22 | 2006-01-26 | E-L Management Corp. | Dissolvable film composition |
US20090202582A1 (en) * | 2008-02-07 | 2009-08-13 | Mibelle Ag | Water-Disposable or Water-Soluble Polymer Film as a Vehicle for Dermatologic and Cosmetic Active Agents |
US20110311611A1 (en) * | 2010-06-22 | 2011-12-22 | Charlene Cheuk Ling Ng | Water dissolvable adherent article for topical application |
WO2012087517A2 (en) * | 2010-12-22 | 2012-06-28 | Avon Products, Inc. | Cosmetic films |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50149682U (zh) * | 1974-05-30 | 1975-12-12 | ||
US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
US4863738A (en) * | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5264219A (en) * | 1992-08-07 | 1993-11-23 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery backing |
GB2306885B (en) * | 1995-11-08 | 1999-07-14 | Reckitt & Colmann Prod Ltd | Supersaturated Pharmaceutical Compositions |
JP3595056B2 (ja) * | 1996-02-09 | 2004-12-02 | 花王株式会社 | シート状化粧料組成物 |
US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
US20020187181A1 (en) * | 2001-05-14 | 2002-12-12 | 3M Innovative Properties Company | System for delivering cosmetics and pharmaceuticals |
US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
US6897348B2 (en) * | 2001-12-19 | 2005-05-24 | Kimberly Clark Worldwide, Inc | Bandage, methods of producing and using same |
DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
DE10317692A1 (de) * | 2003-04-17 | 2004-11-11 | Lts Lohmann Therapie-Systeme Ag | Medizinische Wirkstoffpflaster mit veringerter optischer Auffälligkeit auf der Haut |
US9248146B2 (en) * | 2003-10-24 | 2016-02-02 | Adhesives Research, Inc. | Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents |
JP2005225848A (ja) * | 2004-02-12 | 2005-08-25 | Matsumoto Trading Co Ltd | 化粧用シート |
KR20070053267A (ko) * | 2004-08-20 | 2007-05-23 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 반투명 보호 필름을 갖는 경피 약물 전달 장치 |
US20070148213A1 (en) * | 2005-12-22 | 2007-06-28 | Sayed Ibrahim | Film containing compositions |
US20070259029A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water-dispersible patch containing an active agent for dermal delivery |
EP2448548B1 (en) * | 2010-07-22 | 2017-03-01 | The Procter and Gamble Company | Method for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina |
AU2012204164A1 (en) * | 2011-01-07 | 2013-07-25 | Allergan, Inc. | Melanin modification compositions and methods of use |
CN111700838A (zh) * | 2012-04-20 | 2020-09-25 | 宝洁公司 | 用于改善面部毛孔外观的组合物和方法 |
KR102396906B1 (ko) * | 2013-12-31 | 2022-05-13 | 존슨 앤드 존슨 컨수머 인코포레이티드 | 다층의 형상화된 필름을 형성하기 위한 방법 |
-
2016
- 2016-06-22 CA CA2988152A patent/CA2988152A1/en not_active Abandoned
- 2016-06-22 EP EP16802175.6A patent/EP3310327A2/en active Pending
- 2016-06-22 US US15/189,474 patent/US20160367490A1/en not_active Abandoned
- 2016-06-22 RU RU2018102105A patent/RU2704809C2/ru active
- 2016-06-22 KR KR1020187001558A patent/KR20180018793A/ko unknown
- 2016-06-22 CN CN201680036309.3A patent/CN107771071A/zh active Pending
- 2016-06-22 MX MX2017016787A patent/MX2017016787A/es unknown
- 2016-06-22 RU RU2018102104A patent/RU2751639C2/ru active
- 2016-06-22 KR KR1020187001561A patent/KR20180019198A/ko unknown
- 2016-06-22 BR BR112017027750A patent/BR112017027750B8/pt active IP Right Grant
- 2016-06-22 CA CA2988559A patent/CA2988559A1/en not_active Abandoned
- 2016-06-22 MX MX2017016786A patent/MX2017016786A/es unknown
- 2016-06-22 CN CN201680036271.XA patent/CN107771070A/zh active Pending
- 2016-06-22 AU AU2016284311A patent/AU2016284311B2/en active Active
- 2016-06-22 WO PCT/US2016/038646 patent/WO2016209882A2/en active Application Filing
- 2016-06-22 JP JP2017566298A patent/JP2018519294A/ja active Pending
- 2016-06-22 MA MA045906A patent/MA45906A/fr unknown
- 2016-06-22 JP JP2017566287A patent/JP2018518500A/ja active Pending
- 2016-06-22 WO PCT/US2016/038642 patent/WO2016209880A1/en active Application Filing
- 2016-06-22 US US15/189,505 patent/US20160367491A1/en not_active Abandoned
- 2016-06-22 BR BR112017027595A patent/BR112017027595A2/pt not_active Application Discontinuation
- 2016-06-22 MA MA046079A patent/MA46079A/fr unknown
- 2016-06-22 EP EP16736320.9A patent/EP3310326B1/en active Active
- 2016-06-22 AU AU2016284313A patent/AU2016284313B2/en active Active
-
2018
- 2018-09-17 HK HK18111930.0A patent/HK1252628A1/zh unknown
- 2018-09-17 HK HK18111929.3A patent/HK1252627A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006009987A2 (en) * | 2004-06-22 | 2006-01-26 | E-L Management Corp. | Dissolvable film composition |
US20090202582A1 (en) * | 2008-02-07 | 2009-08-13 | Mibelle Ag | Water-Disposable or Water-Soluble Polymer Film as a Vehicle for Dermatologic and Cosmetic Active Agents |
US20110311611A1 (en) * | 2010-06-22 | 2011-12-22 | Charlene Cheuk Ling Ng | Water dissolvable adherent article for topical application |
WO2012087517A2 (en) * | 2010-12-22 | 2012-06-28 | Avon Products, Inc. | Cosmetic films |
Non-Patent Citations (1)
Title |
---|
杨彤主编: "《美容药物学》", 30 April 2007, 中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112752571A (zh) * | 2018-07-03 | 2021-05-04 | 蓝莓疗法有限公司 | 组合物和治疗方法 |
CN114025851A (zh) * | 2019-07-03 | 2022-02-08 | 株式会社资生堂 | 保湿用膜化妆料 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107771071A (zh) | 用于向皮肤提供有益效果的多层局部施用的制品 | |
RU2750210C2 (ru) | Набор и способ для местной доставки полезных эффектов | |
US20210093072A1 (en) | System for targeted application of topical agents to an isolated body part | |
KR101179900B1 (ko) | 집중 케어와 총체적 트리트먼트를 동시에 전달할 수 있는 트리트먼트 용품 | |
CA2941047A1 (en) | Compositions and methods for treating blackheads | |
JP2004123662A (ja) | 角質除去シート | |
KR20050033848A (ko) | 피부의 상이한 영역에 대한 활성제 적용을 위한 제품 | |
JP4160474B2 (ja) | 角質改善用積層シート |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180306 |